Compare ESPR & PHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | PHR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 713.2M |
| IPO Year | 2013 | 2019 |
| Metric | ESPR | PHR |
|---|---|---|
| Price | $1.90 | $9.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 18 |
| Target Price | $8.75 | ★ $21.18 |
| AVG Volume (30 Days) | ★ 7.4M | 2.7M |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.71 | ★ 103.92 |
| EPS | N/A | ★ 0.04 |
| Revenue | $403,135,000.00 | ★ $480,591,000.00 |
| Revenue This Year | N/A | $8.43 |
| Revenue Next Year | $12.81 | $5.10 |
| P/E Ratio | ★ N/A | $220.25 |
| Revenue Growth | ★ 21.31 | 14.48 |
| 52 Week Low | $0.73 | $7.77 |
| 52 Week High | $4.18 | $32.76 |
| Indicator | ESPR | PHR |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 46.87 |
| Support Level | $1.34 | $7.78 |
| Resistance Level | $2.08 | $12.68 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 11.89 | 79.90 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.